#United States #San Francisco #Hagens Berman #ARD-101 #Aardvark

Hagens Berman Invites Investors of Aardvark Therapeutics to Join Class Action Suit

On September 3, 2026, the national shareholder rights firm, Hagens Berman Sobol Shapiro LLP, formally notified investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) about a pending class action lawsuit concerning potential securities fraud. This informs affected individuals about their legal rights and encourages them to consider joining the lawsuit aimed at recovering damages.

Background of the Lawsuit

The lawsuit arises from claims that Aardvark Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting bitter taste receptors, made several materially false statements and failed to disclose essential information regarding its product, ARD-101. Investors who bought Aardvark's common stock through the company’s initial public offering (IPO) or purchased shares between February 13, 2025, and May 14, 2026, are particularly advised to reach out to Hagens Berman to discuss their case.

The complaint alleges that Aardvark misrepresented the safety and efficacy of ARD-101, which is being developed for the treatment of hyperphagia in Prader-Willi Syndrome. Notably, the defendants failed to reveal important data regarding adverse cardiac events during clinical trials, which they suggested were minor or manageable. Instead, substantial safety concerns were found in these trials, particularly at elevated doses, leading to significant overstatements of the company's commercial and clinical prospects.

Events That Triggered the Class Action

The class action lawsuit was spurred into action following alarming developments in 2026. On February 27, Aardvark announced a voluntary pause in its Phase 3 HERO trial, citing reversible cardiac issues found during routine monitoring. This shocking reveal resulted in a staggering decline of over 56% in the company’s stock price.

Shortly thereafter, on May 14, the Food and Drug Administration (FDA) imposed a full clinical hold on Aardvark's investigational new drug application for ARD-101, halting all studies linked to it. Following these disclosures, the company's stock value fell by another 32.1%, drawing attention to the potential damages suffered by investors.

Legal Steps and Deadlines

Reed Kathrein, the partner leading the investigation at Hagens Berman, emphasizes the importance of understanding the claims about misleading information surrounding ARD-101’s development, emphasizing potential harm for investors. Those who believe they were financially impacted by Aardvark's actions have until October 13, 2026, to request appointment as Lead Plaintiff in the class action suit. This is a critical deadline for investors wishing to represent their interests in court.

Investors are encouraged to reach out to Hagens Berman directly, either by visiting their dedicated website for this case or by calling their office. The firm offers insights and guidance related to individual legal rights and potential recovery paths for those affected.

Whistleblower Opportunities

In addition to investors, the law firm encourages individuals with insider knowledge about Aardvark Therapeutics to report their information potentially benefiting the ongoing investigation. Whistleblowers can receive rewards if their information leads to a successful recovery through the SEC’s Whistleblower program.

Conclusion

As this case unfolds, investors are advised to remain informed and proactive regarding their rights and options. Hagens Berman’s ongoing investigations aim to hold corporations accountable for their actions and provide recovery avenues for those harmed by misleading information. Aardvark's saga serves as a reminder of the importance of transparency in the biopharmaceutical sector and the collective responsibility of stakeholders navigating potential fraud.

For more information or to submit claims, potential class members are urged to contact Hagens Berman at the provided contact details.